AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

2.160

+0.0200.93%

Volume:4.40M

Turnover:9.48M

Market Cap:2.79B

PE:-20.18

High:2.180

Open:2.070

Low:2.070

Close:2.140

52wk High:3.310

52wk Low:1.515

Shares:1.29B

Float Shares:786.49M

Volume Ratio:1.48

T/O Rate:0.56%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.107

EPS(LYR):-0.123

ROE:-18.22%

ROA:-6.16%

PB:3.33

PE(LYR):-17.56

Loading ...

Overview Company News Filings

Mesoblast H1 2026 Loss Of US$94.4 Million Tests Bullish Profitability Narratives

Simply Wall St.

Why Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Detailed Ryoncil Revenue Guidance

Simply Wall St.

Mesoblast Posts HY Total Revenues $51.3 Million

ASX Biggest Losers

MT Newswires Live

BRIEF-Mesoblast Sees Full-Year Fiscal 2026 Ryoncil Net Revenue To Range Between $110 Million And $120 Million

Mesoblast posts H1 FY2026 revenue of USD 51.3 million, 16.0x

Ryoncil® Profits Underpinning Substantial Growth Pipeline

THOMSON REUTERS

Stock Track | Mesoblast Ltd Plummets 5.17% Intraday on Half-Year Loss and Revenue Guidance

Press Release: Ryoncil(R) Profits Underpinning Substantial Growth Pipeline

Stock Track | Mesoblast Soars 5.79% Intraday on Positive Ryoncil Revenue Guidance

Mesoblast Ltd - Sees Full-Year Fiscal 2026 Ryoncil Net Revenue to Range Between US$110 Million and US$120 Million

THOMSON REUTERS

Mesoblast Ltd - Hy Total Revenues $51.3 Mln

THOMSON REUTERS

Mesoblast Ltd expected to post a loss of 7 cents a share - Earnings Preview

Mesoblast Limited to Host Half-Year Financial Results Webcast

Mesoblast (ASX:MSB) Valuation In Focus As Ryoncil Data And New Trial Plan Signal Clinical Momentum

Simply Wall St.

Mesoblast (ASX:MSB) Is Up 6.7% After Adult Ryoncil Data Readout Validates Earlier Second-Line Use

Simply Wall St.

Mesoblast Reports High Survival With Ryoncil in SR-aGvHD and Plans Adult Pivotal Trial

Stock Track | Mesoblast Soars 6.73% Intraday as JPMorgan Chase Becomes Substantial Holder

Mesoblast Says JPMorgan Chase Becomes Substantial Holder; Shares Rise 6%

MT Newswires Live

Stock Track | Mesoblast Plummets 5.02% Intraday Amid Ryoncil Expansion Plans and Financial Concerns

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MSB.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.16,"timestamp":1774933920000,"preClose":2.14,"halted":0,"volume":4404299,"delay":0,"changeRate":0.009345794392523372,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1290302187,"eps":-0.10704907658624227,"marketStatus":"Not Yet Opened","change":0.02,"latestTime":"03-31 16:12:00 AEDT","open":2.07,"high":2.18,"low":2.07,"amount":9475091,"amplitude":0.051402,"askPrice":2.18,"askSize":17849,"bidPrice":2.12,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.10704907658624227,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1774998000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":2.14,"openAndCloseTimeList":[[1774911600000,1774933200000]],"volumeRatio":1.477222,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.14,"auctionPrice":2.15,"auctionVolume":698933,"auction":3,"marketStatus":"盘后竞价","timestamp":1774933801808}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-6.16%","roe":"-18.22%","lyrEps":-0.123028,"volumeRatio":1.477222,"shares":1290302187,"dividePrice":0,"high":2.18,"amplitude":0.051402,"preClose":2.14,"low":2.07,"week52Low":1.515,"pbRate":"3.33","psRate":"29.30","week52High":3.31,"institutionHeld":0,"latestPrice":2.16,"committee":-0.844953,"eps":-0.10704907658624227,"divideRate":0,"volume":4404299,"delay":0,"ttmEps":-0.10704907658624227,"open":2.07,"prevYearClose":2.72,"prevWeekClose":2.11,"prevMonthClose":2.24,"prevQuarterClose":2.72,"fiveDayClose":2.06,"twentyDayClose":2.01,"sixtyDayClose":2.76,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2616227846","title":"Mesoblast H1 2026 Loss Of US$94.4 Million Tests Bullish Profitability Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2616227846","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616227846?lang=en_us&edition=fundamental","pubTime":"2026-03-01 01:28","pubTimestamp":1772299685,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) opened H1 2026 with revenue of US$14.0 million and a basic EPS loss of US$0.04, while trailing 12 month figures in the dataset show revenue of US$65.4 million and a net loss of US$94.4 million. The company has seen revenue move from US$2.5 million in H2 2024 to US$3.2 million in H1 2025 and then to US$14.0 million in H2 2025, with basic EPS losses in those periods ranging between US$0.04 and US$0.05. The latest results therefore keep the focus on how quickly revenue can...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-h1-2026-loss-of-us944-million-tests-bullish-profit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-h1-2026-loss-of-us944-million-tests-bullish-profit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BLSG","MSB.AU","BK4112","BK4139","BK7067","BK7508","BLSX","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614868789","title":"Why Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Detailed Ryoncil Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2614868789","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614868789?lang=en_us&edition=fundamental","pubTime":"2026-02-27 23:46","pubTimestamp":1772207166,"startTime":"0","endTime":"0","summary":"Mesoblast Limited recently reported half-year 2025 results, with revenue rising to US$51.34 million and net loss and loss per share both narrowing, and subsequently issued fiscal 2026 guidance calling for US$110 million to US$120 million in Ryoncil net revenue.\nThis combination of sharply higher reported revenue and the first detailed full-year outlook for Ryoncil offers investors a clearer view of Mesoblast’s early commercial trajectory and cost profile.\nWe’ll now examine how Mesoblast’s...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-down-71-after-issuing-first-detailed","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-down-71-after-issuing-first-detailed","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614001990","title":"Mesoblast Posts HY Total Revenues $51.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614001990","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614001990?lang=en_us&edition=fundamental","pubTime":"2026-02-27 10:13","pubTimestamp":1772158413,"startTime":"0","endTime":"0","summary":"Feb 27 (Reuters) - Mesoblast Ltd ::*HY TOTAL REVENUES $51.3 MILLION*HY LOSS ATTRIBUTABLE $40.2 MILLION*Further company coverage: MSB.AX* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 27-FEB-202602:03:10 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nRSD2kTnKS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614001368","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2614001368","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614001368?lang=en_us&edition=fundamental","pubTime":"2026-02-27 10:02","pubTimestamp":1772157763,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest losses on Friday.Coles Group : -9%, AU$20.12Liontown : -7%, AU$1.6850Harvey Norman Holdings : -7%, AU$5.86Worley : -6%, AU$10.95Mesoblast : -6%, AU$2.27IGO : -4%, AU$8.53NEXTDC : -4%, AU$13.72TPG Telecom : -4%, AU$3.89Perenti : -3%, AU$2.3550Genesis Energy  : -3%, AU$1.96","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7040","BK7504","WOR.AU","BK7055","BK7503","BK7108","BK7095","HVN.AU","BK7041","TPG.AU","IGO.AU","BK7006","BK7508","BK7507","NXT.AU","COL.AU","PRN.AU","BK7501","BK7067","LTR.AU","BK7082","BK7043","MSB.AU","BK7042","BK7153","GNE.AU","BK7506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614009566","title":"BRIEF-Mesoblast Sees Full-Year Fiscal 2026 Ryoncil Net Revenue To Range Between $110 Million And $120 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614009566","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614009566?lang=en_us&edition=fundamental","pubTime":"2026-02-27 09:41","pubTimestamp":1772156490,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Sees Full-Year Fiscal 2026 Ryoncil Net Revenue To Range Between $110 Million And $120 MillionFeb 27  - Mesoblast Ltd MSB.AX:SEES FULL-YEAR FISCAL 2026  RYONCIL NET REVENUE TO RANGE BETWEEN  US$110 MILLION AND US$120 MILLIONFurther company coverage: MSB.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZM249:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK4139","BK7501","BK7067","MESO","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614005300","title":"Mesoblast posts H1 FY2026 revenue of USD 51.3 million, 16.0x","url":"https://stock-news.laohu8.com/highlight/detail?id=2614005300","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614005300?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:43","pubTimestamp":1772153001,"startTime":"0","endTime":"0","summary":"Mesoblast posts H1 FY2026 revenue of USD 51.3 million, 16.0x               Mesoblast (MESO) reported H1 FY2026 total revenue of USD 51.3 million, up from USD 3.2 million, driven by the U.S. commercial","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL7Jkf4x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014005.SGD","BK4585","BK7067","LU2095319765.USD","IE00B64PRP62.GBP","BK4112","BK7508","LU2210149790.SGD","NDAQ","MSB.AU","SG9999014021.USD","LU0314104364.USD","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD","BK7501","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614053220","title":"Ryoncil® Profits Underpinning Substantial Growth Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2614053220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614053220?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:42","pubTimestamp":1772152974,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nTUA6XZHMM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","MSB.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107120223","title":"Stock Track | Mesoblast Ltd Plummets 5.17% Intraday on Half-Year Loss and Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1107120223","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107120223?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:42","pubTimestamp":1772152954,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock price plummeted 5.17% during intraday trading on Friday, following the release of the company's financial results and guidance.The biotech company reported a half-year loss...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614005533","title":"Press Release: Ryoncil(R) Profits Underpinning Substantial Growth Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2614005533","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614005533?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:42","pubTimestamp":1772152920,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 26, 2026  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2025 .Performance driven by successful commercial launch of Ryoncil. -- Total revenue of US$51.3 million ,2 up from US$3.2. generated gross sales of US$57.0 million and revenue of US$48.7 million. -- Ryoncil gross profit, excluding amortization, was US$44.2 million. versus nil in the prior year period. Direct selling costs were US$7.7. -- The strong operating performance in the period allowed us to invest in. R&D, including to support the Phase 3 trial on the blockbuster chronic. -- Reported net loss of US$40.2 million compared to US$47.9 million, an. improvement of US$7.8 million. Excluding a US$23.0 million inventory. -- Net operating cash spend of US$30.3 million. Mesoblast expects to see. -- Period-end cash balance of US$130.0 million. Mesoblast entered into a. US$125.0 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2637428348.USD","BK4585","BK4588","CMS","BK4575","LU0949170772.SGD","BK7508","BK4139","LU1894683348.USD","MESO","R","LU2346227817.USD","BK4022","LU0553294199.USD","LU1894683264.USD","LU0661504455.SGD","MSB.AU","BK4232","BK4208","LU2500361329.USD","BK4150","LU0738911758.USD","LU1003077747.HKD","BK7067","BK7501","LU0545039389.USD","MSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128522861","title":"Stock Track | Mesoblast Soars 5.79% Intraday on Positive Ryoncil Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1128522861","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128522861?lang=en_us&edition=fundamental","pubTime":"2026-02-27 07:03","pubTimestamp":1772146980,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock surged 5.79% during intraday trading on Friday, marking a significant upward movement for the biotech company.The sharp rise appears to be driven by the company's optimistic...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614717700","title":"Mesoblast Ltd - Sees Full-Year Fiscal 2026  Ryoncil Net Revenue to Range Between  US$110 Million and US$120 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614717700","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614717700?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:50","pubTimestamp":1772142640,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZM249:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MESO","BK7067","BK7508","BK4139","BK7501","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614071169","title":"Mesoblast Ltd - Hy Total Revenues $51.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614071169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614071169?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:44","pubTimestamp":1772142247,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZM297:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7508","BK7067","BK4139","MESO","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614856530","title":"Mesoblast Ltd  expected to post a loss of 7 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2614856530","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614856530?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:10","pubTimestamp":1772017813,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd  expected to post a loss of7cents a share - Earnings Preview Mesoblast Ltd MESO.OQ, MESO.O is expected to  report resultson February 27 for the period ending September 30 2025The Melbour","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL8N3ZL106:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MSB.AU","BK7501","BK7067","BK7508","MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612340261","title":"Mesoblast Limited to Host Half-Year Financial Results Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2612340261","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612340261?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:00","pubTimestamp":1771588846,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire  on February 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL5qVvJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210149790.SGD","SG9999014021.USD","SG9999014039.USD","LU0314104364.USD","BK7067","SG9999014013.SGD","BK7501","MSB.AU","IE00BKPKM429.USD","NDAQ","SG9999014005.SGD","BK4585","BK7508","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612286639","title":"Mesoblast (ASX:MSB) Valuation In Focus As Ryoncil Data And New Trial Plan Signal Clinical Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2612286639","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612286639?lang=en_us&edition=fundamental","pubTime":"2026-02-19 19:21","pubTimestamp":1771500069,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) has presented new clinical data for Ryoncil to transplant specialists, reporting consistently high survival outcomes in steroid refractory acute graft versus host disease across multiple patient groups.\nSee our latest analysis for Mesoblast.\nThe latest Ryoncil data arrives after a mixed price run, with Mesoblast’s 90 day share price return of 4.76% contrasting with a 12.64% decline year to date and a three year total shareholder return of 164.49%. This suggests long term...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-in-focus-as-ryoncil-data-and-new","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-in-focus-as-ryoncil-data-and-new","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK7508","BK4006","MSB.AU","BK7067","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611151472","title":"Mesoblast (ASX:MSB) Is Up 6.7% After Adult Ryoncil Data Readout Validates Earlier Second-Line Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2611151472","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611151472?lang=en_us&edition=fundamental","pubTime":"2026-02-13 16:38","pubTimestamp":1770971928,"startTime":"0","endTime":"0","summary":"In February 2026, Mesoblast reported data from patients treated under the U.S. Emergency Investigational New Drug program showing that its FDA-approved cell therapy Ryoncil® (remestemcel-L-rknd) achieved similarly high survival outcomes in steroid-refractory acute graft-versus-host disease across children and adults, at different treatment lines and regardless of ruxolitinib use or resistance.\nThe findings, which highlighted better completion of treatment and survival when Ryoncil was used...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-67-after-adult-ryoncil-data-readout-v","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-67-after-adult-ryoncil-data-readout-v","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4006","BK7508","MSB","BK7501","MSB.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610603319","title":"Mesoblast Reports High Survival With Ryoncil in SR-aGvHD and Plans Adult Pivotal Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2610603319","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610603319?lang=en_us&edition=fundamental","pubTime":"2026-02-12 07:28","pubTimestamp":1770852483,"startTime":"0","endTime":"0","summary":"Mesoblast Limited has announced new data presented at the February 2026 meetings of the American Society for Transplantation and Cellular Therapy  and the Center for Blood and Marrow Transplant Research . The results showed that Ryoncil  achieved similarly high survival outcomes in steroid-refractory acute graft-versus-host disease  when used in both children and adults, regardless of whether it was used as a second or third line treatment, and in patients who were either naive or resistant to ruxolitinib. Ryoncil is currently the only FDA-approved mesenchymal stromal cell product for any indication and is approved for children under age 12 with SR-aGvHD. Mesoblast plans to initiate a pivotal trial to evaluate early use of Ryoncil as a second-line treatment in adults with severe SR-aGvHD, following protocol approval by the central Institutional Review Board. If successful, this trial may support label extension for adult use. The presented results highlight the importance of early trea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL41Dxt1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B64PRP62.GBP","LU2095319765.USD","IE00BKPKM429.USD","SG9999014005.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014039.USD","BK7508","BK4112","LU2210150020.SGD","BK4585","BK7501","SG9999014021.USD","BK7067","MSB.AU","SG9999014013.SGD","LU0314104364.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101862323","title":"Stock Track | Mesoblast Soars 6.73% Intraday as JPMorgan Chase Becomes Substantial Holder","url":"https://stock-news.laohu8.com/highlight/detail?id=1101862323","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101862323?lang=en_us&edition=fundamental","pubTime":"2026-02-09 11:26","pubTimestamp":1770607581,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock surged 6.73% during Monday's intraday trading session, following a significant corporate development.The sharp rise comes after the company disclosed that JPMorgan Chase & Co....","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610507905","title":"Mesoblast Says JPMorgan Chase Becomes Substantial Holder; Shares Rise 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610507905","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610507905?lang=en_us&edition=fundamental","pubTime":"2026-02-09 11:23","pubTimestamp":1770607397,"startTime":"0","endTime":"0","summary":"Mesoblast  received notice that JPMorgan Chase and its affiliates became a substantial holder of the company on Feb. 4, according to a Monday filing with the Australian bourse.JPMorgan Chase now owns 65.2 million shares in the company, representing 5.05% voting power, the filing said.Shares of the company rose 6% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4550","LU2264538146.SGD","LU2054465674.USD","BK4534","LU2023250504.SGD","BK4504","LU1244550577.SGD","LU2430703178.SGD","LU1914381329.SGD","LU1366192091.USD","IE00BKVL7J92.USD","IE00BJTD4N35.SGD","LU0942090050.USD","LU2357305700.SGD","LU2462157665.USD","IE00BN8TJ469.HKD","LU1116320737.USD","IE0034235303.USD","IE00BYXW3230.USD","LU1280957306.USD","MESO","LU2023250843.SGD","LU2552382215.SGD","IE00BDCRKT87.USD","JPM","LU0417517546.SGD","BK4516","LU0149725797.USD","LU1064131342.USD","LU2456880835.USD","LU2592432038.USD","LU1551013342.USD","LU1894683348.USD","LU0238689110.USD","LU0787776722.HKD","LU0971096721.USD","BK4207","LU0320765489.SGD","LU0820562030.AUD","LU2430703251.USD","BK4533","IE00B1BXHZ80.USD","IE00BFXG1179.USD","LU1894683264.USD","LU1032466523.USD","LU0640476718.USD","MSB.AU","LU0256863811.USD","LU0208291251.USD","LU2505996509.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182252637","title":"Stock Track | Mesoblast Plummets 5.02% Intraday Amid Ryoncil Expansion Plans and Financial Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1182252637","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182252637?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:03","pubTimestamp":1770332603,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock plummeted 5.02% during intraday trading on Friday, reflecting significant selling pressure.The price movement follows the company's announcement regarding the expansion of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":2,"totalSize":146,"code":"91000000","status":"200"}]}}